/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained-release dexamethasone products demonstrate positive results in pivotal trials

    Dexamethasone insert 0.4 mg (Dextenza Ocular Therapeutix) met its primary endpoints in a third pivotal trial investigating its efficacy and safety for the treatment of inflammation and pain after cataract surgery, said Eric D. Donnenfeld, MD.

    Presenting data from the prospective, multicenter, randomized, double-masked phase III study, Dr. Donnenfeld said he was excited about the results because he anticipates they will support FDA approval of the intracanalicular insert in the near future.

    “Corticosteroids are a mainstay of cataract surgery medication regimens, but topical regimens are complex, depend on patient compliance, and have the potential to cause ocular surface toxicity at a time when the eye is particularly vulnerable,” said Dr. Donnenfeld, clinical professor of ophthalmology, NYU Langone Medical Center, New York. “The development of alternatives to topical treatment is what it is all about.”

    Dr. Donnenfeld also presented positive results from a phase III study investigating another investigational one-time corticosteroid medication, IBI-10090 (Dexycu, Icon Bioscience). IBI-10090 is a novel, bioabsorbable drug-delivery product for anterior chamber intracameral placement of dexamethasone. It is given as a single 5 µL injection after the completion of cataract surgery.

    The study Dr. Donnenfeld presented showed IBI-100090 demonstrated similar efficacy and safety compared with “standard of care”—topical prednisolone acetate 1.0% four times daily as standard of care.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results